(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 September 2022 (29.09.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/199697 A1

(51) International Patent Classification:
A61K 31/517 (2006.01) *A61P 35/02* (2006.01)
A61K 9/48 (2006.01) *A61P 35/00* (2006.01)
A61K 9/14 (2006.01)

(21) International Application Number:
PCT/CN2022/083127

(22) International Filing Date:
25 March 2022 (25.03.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
202110327776.4 26 March 2021 (26.03.2021) CN

(71) Applicant: **IMPACT THERAPEUTICS (SHANGHAI), INC** [CN/CN]; Room 603, No.3 Building, 111 Xiangke Road, China (shanghai) Pilot Free Trade Zone, Shanghai 201210 (CN).

(72) Inventors: **CAI, Sui Xiong**; Room 3302, No.2, Lane 667, Gaoqing West Road, Pudong New Area, Shanghai 200124 (CN). **MA, Ning**; Room 503, Building 10, No. 9, Yushu Road, Jiangning Dist., Nanjing, Jiangsu 211112 (CN). **ZHAO, Liping**; 12F, New Bund Times Square, 399 Haiyang West Road, Pudong District, Shanghai 200126 (CN). **LIU, Chunhui**; No.288 Fute Zhong Road, Pudong District, Shanghai 200131 (CN). **SHI, Zongfeng**; Room 8-216, 299 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131 (CN).

(74) Agent: **SHANGHAI PATENT & TRADEMARK LAW OFFICE, LLC**; 435 Guiping Road, Shanghai 200233 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2022/199697 A1

(54) Title: ORAL CAPSULE OF PARP INHIBITOR AND PREPARATION METHOD THEREOF

(57) Abstract: An oral capsule formulation of a PARP inhibitor and a preparation method. The oral capsule formulation comprises a solid dispersion powder of an active ingredient 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl)piperazine-1-carbonyl)benzyl)quinazoline-2,4(1H,3H)-dione, a filler, a disintegrant, a glidant, and a lubricant, wherein less than 10 wt.% of the active ingredient in the solid dispersion powder is in a crystalline form. The defects of the fluidity, hygroscopicity and cohesiveness of the solid dispersion powder which result in the difficulty of production scale up of capsule formulation are addressed, and thus commercial scale production can be achieved, and the prepared capsule exhibits proper dissolution rate, excellent storage stability, meanwhile with a reasonable production cost.